DIMSCAN

Digital Imaging Microscopy System

Related Publications

The following publications are related to the DIMSCAN system :

Papers on DIMSCAN development

Authors Paper Name Published in Year
Proffitt RT, Tran JV, Reynolds CP A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates Cytometry 24:204-213 1996
Krejsa J, Frgala F, Alfaro P, Reynolds CP DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates 2002 AACR Annual Meeting (poster) 2002
Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines 2003 AACR Annual Meeting 2003
Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents. 2004 AACR Annual Meeting 2004
Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol.Med., 110: 139-153 2005
Frgala T, Kalous O, Proffitt RT, Reynolds CP A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther, 6(3):886-97 2007

Papers using DIMSCAN

Authors Paper Name Published in Year
Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P Comparison of 13-cis- retinoic acid to trans-retinoic acid using human neuroblastoma cell lines Advances in Neuroblastoma Research 4, Evans A, Biedler JL, Brodeur G, D'Angio GJ, Nakagawara A (eds.), New York: John Wiley & Sons, 237-244 1994
Keshelava N, Seeger RC, Reynolds CP Drug resistance phenotype of neuroblastoma cell lines established at diagnosis and at relapse after induction chemotherapy or bone marrow transplantation European J Cancer33:2002-2006 1997
Anderson CP, Tsai JM, Chan WW, Liu RM, Forman HJ, Reynolds CP Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines European J Cancer 33:2016-2019 1997
Keshelava N, Seeger RC, Groshen S, Reynolds CP Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy Cancer Research 58:5396-5405 1998
Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds G P Depletion of Glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis Experimental Cell Research 246:183-192 1999
Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP N-(4-hydroxypheynl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines J Natl Cancer Inst 91:1138-1146 1999
Keshelava N, Groshen S, Reynolds CP Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines Cancer Chemotherapy and Pharmacology 45:1-8 2000
Chen RL, Reynolds CP, Seeger RC, Cabot MC, Reynolds CP Neutrophils are cytotoxic and growth inhibiting for neuroblastoma cells with anti-GD2 antibody but without cytotoxicity can be growth stimulating Clinical Immunol Immunother 48:603-612 2000
Maurer BJ, Cabot MC, Reynolds CP Synergism of   N-(4-hydroxyphenyl)retinamide cytotoxicity by modulators of ceramide metabolism in solid tumor cell lines J Natl Cancer Inst 92:1897-1908 2000
Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide Medical Pediatric Oncology 35:597-602 2000
Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche CJ, Reynolds CP Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines Cancer Research 61:6185-6193 2001
Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line J Pediat Hematol Oncol  23:500-505 2001
Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC Enhanced expression and activation of Mac-1 (CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity Blood 99:4166-4173 2002
O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes Leukemia 16:902-910 2002
Anderson C, Reynolds CP Cytotoxicity of buthionine sulfoximine (BSO) and melphalan/BSO in combination for neuroblastoma cell lines derived after myeloablative therapy Bone Marrow Transplantation 30:135-140 2002
Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith Testing of New Agents in Childhood Cancer Preclinical Models : Meeting Summary Clinical Cancer Research 8:3646-3657 2002
Bo Yang, Nino Keshelava, Clarke P. Anderson, and C. Patrick Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine Cancer Research 63:1520-1526 2003
Nino Keshelava, Denice Tsao-Wei, and C. Patrick Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p531 Clinical Cancer Research 9:3492-3502 2003
Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P. In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol.Med., 110: 87-100 2005
Reynolds, C. P. and Maurer, B. J. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol.Med., 110: 173-183 2005
Yang, B. and Reynolds, C. P. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin.Cancer Res., 11: 2774-2780 2005
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Tony Ng T, Reynolds CP, Triche TJ, Sorensen PHB E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Research, 67: 3094-3105 2007
Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer, (In Press). 2007
Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute, 99:1107-19 2007
Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer., (In Press) 2007
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 110:205-2066 2007
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer, (In Press) 2007
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer, (In Press) 2007
Reynolds CP, Kang MH, Keshelava N, Mauer BJ Assessing combinations of cytotoxic agents using leukemia cell lines. Current Drug Targets, 8:765-771 2007

Clinical Trials Enabled by DIMSCAN Testing

Authors Paper Name Published in Year
Villablanca JG, Avramis V, Khan A, Matthay KK, Ram say NKC, Seeger RC, Reynolds CP Phase I trial of 13-cis-retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT) J Clinical Oncology 13:894-901 1995
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid New Eng J Med 341:1165-1173 1999
Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krail M, Reynolds CP Phase I trial of oral [N- (-4-hydroxyphenyl) retinamide] (4-HPR) in children with resistant/recurrent solid tumors: A Children's Cancer Group Study (CCG 09709) Proc Amer Soc Clin Oncol 21:398a
J Clinical Oncology 24:3423-3430
2002
2006
Anderson CP, Robert Seeger RC, Bailey H, Reynolds CP Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB) Proc Amer Soc Clin Oncol 21 :298a 2002
New Approaches to Neuroblastoma Therapy N2002-01: A Phase I Study of High-Dose Pyrazoloacridine (PZA) (NSC 366140) Supported with Autologous Hematopoietic Stem Cell Rescue in Children with Recurrent or Resistant Neuroblastoma. Closed  
Children's Oncology Group ANBL0321: A Phase II Study of Fenretinide in Children with Recurrent/Resistant High Risk Neuroblastoma. Ongoing  
New Approaches to Neuroblastoma Therapy N99-02: A Phase I trial of BSO + L-PAM and Stem Cell Support. Ongoing  
Norris Cancer Center A Phase II trial of Fenretinide in Recurrent Ovarian Cancer. Proc Amer Soc Clin Oncol 23:461
Proc Amer Soc Clin Oncol 25: Abst 5555
2004
2007
California Cancer Consortium A Phase II trial of Fenretinide in Prostate Cancer. Ongoing  
California Cancer Consortium A Phase I trial of Intravenous Fenretinide in Hematological Malignancies. Ongoing  
California Cancer Consortium A phase I trial of intravenous fenretinide in solid tumors Ongoing  
California Cancer Consortium A phase II trial of fenretinide in asymptomatic rising PSA prostate cancer Completed  
New Approaches to Neuroblastoma Therapy N2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254) Ongoing  
Therapeutic Advances in Childhood Leukemia TACL 2005-001: A phase I/II trial of ABT-751 combined with dexamethasone, PEG-asparaginase, and doxorubicin in relapsed acute lymphoblastic leukemia (ALL) Ongoing  
Therapeutic Advances in Childhood Leukemia TACL 2005-003: Bortezomib with chemotherapy for relapsed childhood ALL. Ongoing  
Therapeutic Advances in Childhood Leukemia TACL 2006-001: IV Fenretinide in Relapsed ALL, AML or NHL. Ongoing